Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis

被引：0
|
作者：
Pauline A. van Schouwenburg
Theo Rispens
Gerrit Jan Wolbink
机构：
[1] Sanquin Research and Landsteiner Laboratory Academic Medical Centre,Department of Immunopathology
[2] Jan van Breemen Research Institute,Department of Rheumatology
来源：
Nature Reviews Rheumatology | 2013年 / 9卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The presence of anti-drug antibodies (ADA) can result in the loss of response to anti-TNF biologic agents in patients with rheumatoid arthritis. In this article, van Schouwenburg et al. outline the limitations of current assays for ADA detection and discuss how studying the immune responses caused by the different anti-TNF biologic agents could lead to strategies to help reduce or prevent the development of ADA.
引用
收藏
页码：164 / 172
页数：8
相关论文
共 50 条
  • [1] Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis
    van Schouwenburg, Pauline A.
    Rispens, Theo
    Wolbink, Gerrit Jan
    NATURE REVIEWS RHEUMATOLOGY, 2013, 9 (03) : 164 - 172
  • [2] Immunogenicity of anti-TNF biologic agents in the treatment of rheumatoid arthritis
    Mok, Chi Chiu
    Tsai, Wen Chan
    Chen, Der Yuan
    Wei, James Cheng Chung
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2016, 16 (02) : 201 - 211
  • [3] Pharmacological strategies for mitigating anti-TNF biologic immunogenicity in rheumatoid arthritis patients
    Fernandez, Christian A.
    CURRENT OPINION IN PHARMACOLOGY, 2023, 68
  • [4] Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis
    Peter C. Taylor
    Marc Feldmann
    Nature Reviews Rheumatology, 2009, 5 : 578 - 582
  • [5] Rheumatoid Arthritis - Anti-TNF
    Chaabo, Khaldoun
    Kirkham, Bruce
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2015, 27 (02) : 180 - 184
  • [6] Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis
    Taylor, Peter C.
    Feldmann, Marc
    NATURE REVIEWS RHEUMATOLOGY, 2009, 5 (10) : 578 - 582
  • [7] BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies
    Ding, Tina
    Ledingham, Jo
    Luqmani, Raashid
    Westlake, Sarah
    Hyrich, Kimme
    Lunt, Mark
    Kiely, Patrick
    Bukhari, Marwan
    Abernethy, Rikki
    Bosworth, Ailsa
    Ostor, Andrew
    Gadsby, Kate
    McKenna, Frank
    Finney, Diana
    Dixey, Josh
    Deighton, Chris
    RHEUMATOLOGY, 2010, 49 (11) : 2217 - 2219
  • [8] Workplace impacts of anti-TNF therapies in rheumatoid arthritis: review of the literature
    Birnbaum, Howard
    Shi, Lizheng
    Pike, Crystal
    Kaufman, Rebecca
    Sun, Peter
    Cifaldi, Mary
    EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (02) : 255 - 269
  • [9] Clinical opportunities of anti-TNF therapies in rheumatoid arthritis: An international roundtable
    Bathon, JM
    AMERICAN JOURNAL OF MANAGED CARE, 1999, 5 (08): : S480 - S482
  • [10] Anti-TNF agents for rheumatoid arthritis
    Seymour, HE
    Worsley, A
    Smith, JM
    Thomas, SHL
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 51 (03) : 201 - 208
12345